drugset / Trial / NCT06237335
A Phase 2 Study Evaluating Safety and Tolerability of RCT2100 (CFTR mRNA) in Healthy Participants and in Participants With CF
RandomizedParallel-groupDouble-blindTreatment
Summary
This is the first-in-human study with RCT2100 and is designed to provide safety and tolerability data for future clinical studies.
Timeline
- Start
- 2024-02-01
- Primary completion
- 2026-08-30
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | RCT2100 | Messenger RNA (mRNA) | — | Inhaled |
| Background | Ivacaftor | Other / unclassified | — | Oral |